On Jun. 13, 2020, Dr. Reddy’s Laboratories announced that it had entered into a non-exclusive Licensing Agreement with Gilead Sciences that granted Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India.